

Special Issue

Allergic Rhinitis: From Pathology to Novel Therapeutic Approaches

Message from the Guest Editor

We are pleased to announce a new Special Issue in *Biomedicines*, titled “Allergic Rhinitis: From Pathology to Novel Therapeutic Approaches”, and invite you to submit your original research or review articles to this collection. This Special Issue aims to bridge mechanistic insights into allergic rhinitis (AR) with cutting-edge therapeutic strategies. We welcome submissions exploring topics including (but not limited to) the following: immune dysregulation and molecular pathways, driving AR pathology; biomarker discovery for diagnosis, prognosis, or treatment response prediction; novel immunotherapies; microbiome–host interactions in AR development and progression; and precision medicine approaches integrating omics technologies or AI-driven models. Accepted papers after peer review will be published in this Open Access issue, ensuring global visibility and impact. Please let us know if you are interested in submitting work to this Special Issue.

Guest Editor

Prof. Dr. Shaoqing Yu

1. Department of Otolaryngology, Tongji Hospital, School of Medicine, Tongji University, Shanghai 20065, China
2. Department of Allergy, Tongji Hospital, School of Medicine, Tongji University, Shanghai 200065, China

Deadline for manuscript submissions

closed (31 May 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/237907

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).